Regeneron Pharmaceuticals Inc (WBO:REGN)
€ 757.4 -20.4 (-2.62%) Market Cap: 83.82 Bil Enterprise Value: 77.30 Bil PE Ratio: 20.53 PB Ratio: 3.11 GF Score: 99/100

Regeneron Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 10, 2022 / 03:30PM GMT
Release Date Price: €542.8 (+2.26%)
Cory William Kasimov
JPMorgan Chase & Co, Research Division - Senior Biotechnology Analyst

Great. Good morning, and once again, welcome to the 40th Annual, and unfortunately, second-time virtual JPMorgan Healthcare Conference. My name is Cory Kasimov. I'm the senior large-cap biotech analyst. And it's my pleasure to introduce our next company to present, which is Regeneron. Representing Regeneron are the company's cofounders, CEO, Len Schleifer; and CSO, George Yancopoulos.

Please note that following this presentation, we'll go right in to Q&A, where you can submit questions via the Ask a Question button on your conference portal and we'll work in as many as we can, time permitting.

So with that, let me turn things over to Len.

Leonard S. Schleifer
Regeneron Pharmaceuticals, Inc. - Co-Founder, President, CEO & Executive Director

Thanks, Cory. We've been getting introductions for 30 years, and that's one of the more stellar ones.

All kidding aside, we were hoping for something like live from New York, it's Regeneron.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot